Peptides for Injury Recovery

An acute injury is a different problem from everyday training soreness. A tendon tear or ligament sprain has to rebuild structure, and both tissues start at a disadvantage: their blood supply is poor, which is a large part of why they recover slowly and why rehabilitation runs to months rather than weeks.

The tissue repair peptides here are studied for the early stages of that rebuild. BPC-157 is best known for angiogenesis, the growth of new blood vessels into damaged tissue, and for fibroblast recruitment, drawing in the cells that lay down new collagen. TB-500, a synthetic version of thymosin beta-4, acts on actin, the scaffolding cells use to move, which supports cell migration toward the injury.

None of this replaces a diagnosis, loading work or physical therapy. The research question is whether these signals may support the repair your rehab is already driving, and results vary.

The honest answer is: not much yet. A 2025 systematic review screened 544 papers on BPC-157 and found 36 that met its criteria; 35 of them were preclinical, meaning cells and animals. The human evidence is a small number of uncontrolled studies from a limited set of sources, such as a knee-pain case series with no comparison group. That kind of study cannot separate a drug effect from natural recovery or placebo.

TB-500's parent molecule, thymosin beta-4, went further and reached Phase 2 human trials, but for wound and cardiac repair, not sports injuries. No peptide in this category has a completed Phase 2 or Phase 3 trial for tendon, ligament or muscle injury.

That does not make the mechanism fiction. The animal data is consistent across decades and tissue types, which is why researchers keep studying it. But an evidence-based view of peptide therapy for injury recovery is that it is plausible and unproven in people, and we prescribe it with that stated plainly.

If you compete in any sport with drug testing, this section matters more than anything else on the page. BPC-157 has been named on the World Anti-Doping Agency (WADA) Prohibited List since January 1, 2022, as a non-approved substance. TB-500 is prohibited as a growth factor and has been named on the list since 2018. Both are banned at all times, in and out of competition, and no medical exemption is available for BPC-157.

This is not only an Olympic problem. The rules reach amateur, masters and university competition under WADA-based programs, and bodies like the NCAA keep their own banned lists. In 2024 a Canadian university volleyball player received a four-year ban for using this exact pair, without ever failing a drug test.

A violation can cost you multiple seasons. If you are subject to testing, do not use these products, and tell your provider about your sport.

All three injectables share BPC-157; the difference is how wide each one casts the net.

BPC-157 alone fits one localized injury: a single tendon, a single ligament. For people researching peptides for tendon repair it is the usual starting point, because its research centers on local repair at the damaged site.

[BPC/TB-500](/peptides/bpc-tb500) adds TB-500's whole-body reach. It fits injuries with more than one site involved, or recovery after a surgical repair where the surrounding tissue matters too.

[KLOW](/peptides/klow) is the broadest stack, adding GHK-Cu and KPV to the same pair for collagen and inflammatory signaling.

Prefer capsules to injections? The format question, including BPC/TB-500 Capsules, is covered on our Recovery page. A provider matches the stack to your diagnosis.

The right candidate is an adult with a diagnosed soft-tissue injury who wants clinical oversight alongside rehab, not instead of it. A fresh injury with severe pain, numbness, instability or loss of function needs an in-person exam and often imaging first; these peptides do not replace physical therapy or surgery.

Pregnancy and breastfeeding are hard stops. Active cancer rules out the TB-500 products and KLOW and needs a provider conversation before BPC-157, since both peptides support blood vessel growth. KLOW's copper peptide also rules it out with Wilson's disease or copper sensitivity. Side effects are usually mild, mostly injection-site redness.

None of these is FDA-approved, and compounded medications require a valid prescription.

Starting peptides for injury recovery at PeRx takes three steps and no office visit.

First, take the 60-second assessment. Describe the injury, your history and your sport. Choose your peptide and save a card; you are not charged yet.

Second, a licensed US provider reviews your file. If they approve, they write the prescription and set the dose, and only then is your card charged.

Third, it ships ready to use, with syringes, alcohol swabs and instructions.

Take the 60-second assessment, or talk to us first.